+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pruritus - Pipeline Review, H2 2019

  • ID: 4866520
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 185 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Albireo Pharma Inc
  • Asana BioSciences LLC
  • DermaXon LLC
  • MC2 Therapeutics AS
  • Roivant Sciences Ltd
  • Teikoku Pharma USA Inc
  • MORE
Pruritus - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Pruritus - Pipeline Review, H2 2019, provides an overview of the Pruritus (Dermatology) pipeline landscape.

Pruritus, or itch, is defined as an unpleasant sensation that provokes the desire to scratch. Pruritus is caused by cancer, cancer treatments, infection, dry skin and reaction to a drug. Symptoms include redness, bumps, spots or blisters, dry, cracked skin and leathery or scaly texture to the skin. Risk factors include heat, allergic, asthma, hay fever, hives and eczema. Treatment includes corticosteroids, antihistamines and antidepressants.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Pruritus - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Pruritus (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pruritus (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 12, 6, 1, 14, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Pruritus (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pruritus (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Pruritus (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pruritus (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pruritus (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pruritus (Dermatology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pruritus (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pruritus (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Albireo Pharma Inc
  • Asana BioSciences LLC
  • DermaXon LLC
  • MC2 Therapeutics AS
  • Roivant Sciences Ltd
  • Teikoku Pharma USA Inc
  • MORE
Introduction
Pruritus - Overview
Pruritus - Therapeutics Development
Pruritus - Therapeutics Assessment
Pruritus - Companies Involved in Therapeutics Development
Pruritus - Drug Profiles
Pruritus - Dormant Projects
Pruritus - Discontinued Products
Pruritus - Product Development Milestones
Appendix

List of Tables
Table 1: Number of Products under Development for Pruritus, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Universities/Institutes, H2 2019
Table 5: Products under Development by Companies, H2 2019
Table 6: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 7: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 8: Products under Development by Universities/Institutes, H2 2019
Table 9: Number of Products by Stage and Target, H2 2019
Table 10: Number of Products by Stage and Mechanism of Action, H2 2019
Table 11: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Table 12: Number of Products by Stage and Route of Administration, H2 2019
Table 13: Number of Products by Stage and Molecule Type, H2 2019
Table 14: Pruritus - Pipeline by Albireo Pharma Inc, H2 2019
Table 15: Pruritus - Pipeline by Amgen Inc, H2 2019
Table 16: Pruritus - Pipeline by AntalGenics SL, H2 2019
Table 17: Pruritus - Pipeline by AOBiome LLC, H2 2019
Table 18: Pruritus - Pipeline by Asana BioSciences LLC, H2 2019
Table 19: Pruritus - Pipeline by Biomimetix JV LLC, H2 2019
Table 20: Pruritus - Pipeline by Cara Therapeutics Inc, H2 2019
Table 21: Pruritus - Pipeline by Celgene Corp, H2 2019
Table 22: Pruritus - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2019
Table 23: Pruritus - Pipeline by DermaXon LLC, H2 2019
Table 24: Pruritus - Pipeline by ELORAC Inc, H2 2019
Table 25: Pruritus - Pipeline by GlaxoSmithKline Plc, H2 2019
Table 26: Pruritus - Pipeline by Hydra Biosciences Inc, H2 2019
Table 27: Pruritus - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019
Table 28: Pruritus - Pipeline by Kiniksa Pharmaceuticals Corp, H2 2019
Table 29: Pruritus - Pipeline by Kolmar Korea Holdings Co Ltd, H2 2019
Table 30: Pruritus - Pipeline by Lumosa Therapeutics Co Ltd, H2 2019
Table 31: Pruritus - Pipeline by MC2 Therapeutics AS, H2 2019
Table 32: Pruritus - Pipeline by Menlo Therapeutics Inc, H2 2019
Table 33: Pruritus - Pipeline by Neurim Pharmaceuticals Ltd, H2 2019
Table 34: Pruritus - Pipeline by NeuroCycle Therapeutics GmbH, H2 2019
Table 35: Pruritus - Pipeline by Patagonia Pharmaceuticals LLC, H2 2019
Table 36: Pruritus - Pipeline by Peptide Logic LLC, H2 2019
Table 37: Pruritus - Pipeline by RDD Pharma Ltd, H2 2019
Table 38: Pruritus - Pipeline by Roivant Sciences Ltd, H2 2019
Table 39: Pruritus - Pipeline by Saniona AB, H2 2019
Table 40: Pruritus - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H2 2019
Table 41: Pruritus - Pipeline by Shaperon Inc, H2 2019
Table 42: Pruritus - Pipeline by Sienna Biopharmaceuticals Inc, H2 2019
Table 43: Pruritus - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2019
Table 44: Pruritus - Pipeline by Sunny Pharmtech Inc, H2 2019
Table 45: Pruritus - Pipeline by Teikoku Pharma USA Inc, H2 2019
Table 46: Pruritus - Pipeline by Tioga Pharmaceuticals Inc, H2 2019
Table 47: Pruritus - Pipeline by Toray Industries Inc, H2 2019
Table 48: Pruritus - Pipeline by Trevi Therapeutics Inc, H2 2019
Table 49: Pruritus - Pipeline by Vanda Pharmaceuticals Inc, H2 2019
Table 50: Pruritus - Pipeline by Vivozon Inc, H2 2019
Table 51: Pruritus - Dormant Projects, H2 2019
Table 52: Pruritus - Dormant Projects, H2 2019 (Contd..1), H2 2019
Table 53: Pruritus - Discontinued Products, H2 2019

List of Figures
Figure 1: Number of Products under Development for Pruritus, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products by Top 10 Targets, H2 2019
Figure 4: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 5: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Routes of Administration, H2 2019
Figure 8: Number of Products by Stage and Routes of Administration, H2 2019
Figure 9: Number of Products by Molecule Types, H2 2019
Figure 10: Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Albireo Pharma Inc
  • Amgen Inc
  • AntalGenics SL
  • AOBiome LLC
  • Asana BioSciences LLC
  • Biomimetix JV LLC
  • Cara Therapeutics Inc
  • Celgene Corp
  • Chugai Pharmaceutical Co Ltd
  • DermaXon LLC
  • ELORAC Inc
  • GlaxoSmithKline Plc
  • Hydra Biosciences Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Kiniksa Pharmaceuticals Corp
  • Kolmar Korea Holdings Co Ltd
  • Lumosa Therapeutics Co Ltd
  • MC2 Therapeutics AS
  • Menlo Therapeutics Inc
  • Neurim Pharmaceuticals Ltd
  • NeuroCycle Therapeutics GmbH
  • Patagonia Pharmaceuticals LLC
  • Peptide Logic LLC
  • RDD Pharma Ltd
  • Roivant Sciences Ltd
  • Saniona AB
  • Sanwa Kagaku Kenkyusho Co Ltd
  • Shaperon Inc
  • Sienna Biopharmaceuticals Inc
  • Sumitomo Dainippon Pharma Co Ltd
  • Sunny Pharmtech Inc
  • Teikoku Pharma USA Inc
  • Tioga Pharmaceuticals Inc
  • Toray Industries Inc
  • Trevi Therapeutics Inc
  • Vanda Pharmaceuticals Inc
  • Vivozon Inc
Note: Product cover images may vary from those shown
Adroll
adroll